Blenrep (Belantamab Mafodotin-blmf)
- Medicine Name: Blenrep
- Generic Name: Belantamab Mafodotin-blmf
- Dosage Form & Strength: Injection: 100mg/Vial
- Manufactured By: GlaxoSmithKline
Medical Uses
Blenrep is a BCMA-directed antibody and microtubule inhibitor conjugate used to treat adult patients with relapsed or refractory multiple myeloma (MM) who have received at least 4 prior therapies including a proteasome inhibitor, an anti-CD38 monoclonal antibody, and an immunomodulatory agent.
Recommended Dosage: The recommended dosage of Blenrep injection is 2.5 mg/kg of actual body weight administered as an intravenous infusion over approximately 30 minutes once every 3 weeks until the disease is progressive or in case of unacceptable toxicity.
Warning & Precautions
- Conduct ophthalmic evaluations (visual acuity and slit lamp) at baseline, before each dose, and promptly for worsening signs/symptoms.
- Perform baseline evaluations within three weeks before the first dose. Each follow-up examination needs to be performed at least 1 week after the last dose and within two weeks before the next dose.
- Withhold the BLENREP 100 mg injection until improvement and resume at same or reduced dose, or consider permanently discontinuing on behalf of severity.
- Advise patients to consider preservative-free lubricant eye drops at least 4 times daily starting with the first infusion and continuing until the end of treatment. Do not use contact lenses unless instructed by an ophthalmologist.
- Changes in visual acuity may be linked with difficulty for driving and reading. Advise patients to consider caution while driving or operating machinery.
- Monitor patients for infusion-related reactions. For Grade 2/3 reactions, interrupt the infusion and offer supportive treatment. Once symptoms resolve, resume at a reduced infusion rate.
- On behalf of mechanism of action, Belantamab Mafodotin can cause fetal harm if administered to a pregnant woman because it contains a genotoxic compound (the microtubule inhibitor, monomethyl auristatin F) and it targets actively dividing cells.
- Women should not breastfeed during treatment with Belantamab Mafodotin-blmf and for three months after the last dose.
Documentation & Availability
What documents are required to import BLENREP to India?
BLENREP (Belantamab Mafodotin-blmf) can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of India).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is BLENREP available in India?
BLENREP (Belantamab Mafodotin Injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
BLENREP can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of BLENREP (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for Blenrep price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Sourcing & Delivery
Indian Pharma Network is able to source the BLENREP (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
FAQ
What is the Generic Name for the trade name drug Blenrep®?
Belantamab Mafodotin-blmf is Generic Name for the trade name drug Blenrep®.
What is the Manufacturer Name of Blenrep®?
Blenrep® is manufactured by GlaxoSmithKline.
Is Blenrep® approved by the FDA?
Yes, Blenrep® is approved by the FDA. Date of approval: August 5, 2020.
What is Blenrep® injection?
The Blenrep injection is the FDA approved medication for the treatment of patients with relapsed or refractory multiple myeloma (RRMM).
What is the dosage and form of Blenrep® supplied?
Blenrep® is supplied for injection: 100 mg as a lyophilized powder in a single-dose vial for reconstitution and further dilution.
What are the most common side effects due to Blenrep®?
Most common side effects due to Blenrep® include: nausea, keratopathy (corneal epithelium change on eye exam), decreased visual acuity, pyrexia, infusion-related reactions, blurred vision and fatigue.
What are the storage conditions of Blenrep®?
Store vials of Blenrep® refrigerated at 36°F to 46°F (2°C to 8°C). It is a hazardous agent. Follow the applicable special handling as well as disposal procedures.
How much does Blenrep® cost in India?
The blenrep cost in India is competitive. In order to procure this medication authentically, kindly connect to any WHO-GDP and ISO certified pharmaceutical Wholesaler/Distributor/Supplier.
What are the Highlights of prescribing information for Blenrep®?
Click Here to download full Blenrep prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
